1.07 USD
-0.09 (-7.76%)
At close: Jan 29, 2026
1.02 USD
-0.05 (-4.67%)
Pre-Market: 1/30/2026, 6:25:47 AM
Overall MNDR gets a fundamental rating of 2 out of 10. We evaluated MNDR against 103 industry peers in the Health Care Providers & Services industry. MNDR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MNDR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- MNDR had negative earnings in the past year.
- In the past year MNDR has reported a negative cash flow from operations.
- In the past 5 years MNDR reported 4 times negative net income.
- MNDR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -113.31%, MNDR is doing worse than 92.23% of the companies in the same industry.
- With a Return On Equity value of -192.59%, MNDR is not doing good in the industry: 76.70% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.31% | ||
| ROE | -192.59% | ||
| ROIC | N/A |
ROA(3y)-121.89%
ROA(5y)-86.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MNDR has a Gross Margin of 16.06%. This is in the lower half of the industry: MNDR underperforms 63.11% of its industry peers.
- MNDR's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for MNDR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 16.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.44%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MNDR has less shares outstanding
- MNDR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -9.44, we must say that MNDR is in the distress zone and has some risk of bankruptcy.
- MNDR's Altman-Z score of -9.44 is on the low side compared to the rest of the industry. MNDR is outperformed by 88.35% of its industry peers.
- There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.44 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- A Current Ratio of 1.06 indicates that MNDR should not have too much problems paying its short term obligations.
- The Current ratio of MNDR (1.06) is worse than 66.02% of its industry peers.
- A Quick Ratio of 0.99 indicates that MNDR may have some problems paying its short term obligations.
- MNDR has a worse Quick ratio (0.99) than 66.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
- The earnings per share for MNDR have decreased strongly by -303.19% in the last year.
- The Revenue for MNDR has decreased by -42.16% in the past year. This is quite bad
- The Revenue has been growing slightly by 3.04% on average over the past years.
EPS 1Y (TTM)-303.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325.52%
Revenue 1Y (TTM)-42.16%
Revenue growth 3Y3.04%
Revenue growth 5YN/A
Sales Q2Q%-45.26%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y150%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year76.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- MNDR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 52.45, the valuation of MNDR can be described as expensive.
- MNDR's Price/Forward Earnings is on the same level as the industry average.
- When comparing the Price/Forward Earnings ratio of MNDR to the average of the S&P500 Index (25.72), we can say MNDR is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 52.45 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- MNDR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MOBILE-HEALTH NETWORK SOLUTI / MNDR FAQ
What is the ChartMill fundamental rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MNDR.
What is the valuation status for MNDR stock?
ChartMill assigns a valuation rating of 1 / 10 to MOBILE-HEALTH NETWORK SOLUTI (MNDR). This can be considered as Overvalued.
How profitable is MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?
MOBILE-HEALTH NETWORK SOLUTI (MNDR) has a profitability rating of 0 / 10.
How financially healthy is MOBILE-HEALTH NETWORK SOLUTI?
The financial health rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) is 5 / 10.